Dr. Lal Pathlabs Corporate Filings & Announcements

Healthcare Services company Dr. Lal Pathlabs announced Q2FY26 results Revenue: Rs 731 crore compared to Rs 660 crore during Q2FY25, change 10.7%. EBITDA: Rs 224 crore compared to Rs 202 crore during Q2FY25, change 10.8%. EBITDA Margin: 30.7% for Q2FY26. PBT: Rs 204 crore compared to Rs 183 crore during Q2FY25, change 11.2%. PAT: Rs 152 crore compared to Rs 131 crore during Q2FY25, change 16.4%. Brig Dr Arvind Lal, Executive Chairman, said: “At Dr. Lal PathLabs, we see this decade as one for deep transformation. The burden of chronic and lifestyle-related diseases continues to rise, demanding greater focus on early detection and continuous monitoring. As new therapies for diabetes, hypertension and obesity become more widely available, the role of diagnostics will only intensify. Further, as policy initiatives like Ayushman Bharat expand access across Tier-2 and Tier-3 regions, diagnostics is emerging as the essential first step in care delivery. The growing awareness around preventive health, supported by rapid digital adoption, is helping millions of citizens engage with organized healthcare for the first time. This convergence of accessibility, affordability, and accountability marks a defining moment for the sector, and we are privileged to play a prime role in it. As the shift from unorganized to organized healthcare continues, we stand ready to lead the way responsibly and to contribute meaningfully to India’s ambition of universal healthcare.” Shankha Banerjee, Chief Executive Officer, said: “Q2FY26 marked a healthy revenue growth trajectory on the back of a robust sample volume growth. As we continue to focus on improving patient service, enhancing medical expertise and network expansion, this momentum is expected to continue. We continue to broaden our high-complexity testing capabilities, including Genomics, Oncology, Autoimmunity and others. We are also increasing applications for AI in our operations, including inhouse developed algorithms. Digital and automation initiatives remain central to improving operational efficiency, enhancing patient experience, and supporting scalable growth. Moving forward, growth will be underpinned by geographic expansion, portfolio innovation and digital enablement. Our pricing discipline continues to serve as a powerful lever, and is expected to support movement from unorganized to organized players. Our operational priority remains to maximize network utilization and convert infrastructure into significant operating leverage, ensuring we deliver superior, sustainable, and profitable growth for our shareholders.” Ved Prakash Goel, Group CFO & CEO, said: “Q2FY26 demonstrated steady growth in volumes and favourable business mix, driving sustained financial performance. By maintaining disciplined execution, cost efficiency and a calibrated pricing approach, we have maintained profitability while retaining strategic flexibility for future investments. During the quarter, we further expanded our footprint across underpenetrated markets, supported by new labs and PSCs, while reinforcing engagement with channel partners. This tiered expansion strategy, coupled with completion of back-end integration and merger of Suburban Diagnostics, is helping us unlock new demand pockets and strengthen our leadership in core regions, including Delhi NCR, Mumbai, Pune, and Goa. Strategic digital investments continue to yield tangible ROI. Looking ahead, with a robust balance sheet, strategic investments in technology, and a clearly defined growth roadmap, we are confident of delivering sustainable longterm value and capturing the shift from unorganized to organized diagnostics across India.” Result PDF

25.87% Gain from 52W Low

Dr. Lal Pathlabs Corporate Filings & Announcements

Latest corporate announcements and filings from Dr. Lal Pathlabs on BSE